Halozyme Therapeutics | HALO - Selling And Administration Expenses

Stock Price
67.12
Daily Change
-2.09 -3.02%
Monthly
0.72%
Yearly
29.03%
Q2 Forecast
65.77

Halozyme Therapeutics reported $46.29M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amarin USD 18.97M 1.03M Dec/2025
Amgen USD 1.58B 354M Mar/2026
Baxter International USD 728M 33M Mar/2026
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
DBV Technologies USD 3.63M 3.18M Sep/2025
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Intrexon USD 10.31M 41K Jun/2024
Ionis Pharmaceuticals USD 151M 21M Mar/2026
MannKind USD 54.08M 4.33M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
United Therapeutics USD 156.6M 34M Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024